Analysts Offer Predictions for OTCMKTS:MDNAF FY2030 Earnings

Medicenna Therapeutics Corp. (OTCMKTS:MDNAF) – Analysts at HC Wainwright lowered their FY2030 earnings per share estimates for shares of Medicenna Therapeutics in a note issued to investors on Thursday, July 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.22 per share for the year, down from their prior forecast of $0.23. The consensus estimate for Medicenna Therapeutics’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Medicenna Therapeutics’ FY2031 earnings at $0.33 EPS.

Medicenna Therapeutics (OTCMKTS:MDNAF) last released its quarterly earnings data on Thursday, June 25th. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05).

Medicenna Therapeutics Stock Down 8.6%

Medicenna Therapeutics stock opened at $0.28 on Friday. The business’s 50 day moving average price is $0.35. The company has a market cap of $25.38 million, a price-to-earnings ratio of -1.72 and a beta of 1.75. Medicenna Therapeutics has a 1-year low of $0.25 and a 1-year high of $1.43.

About Medicenna Therapeutics

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.